Jericho Sciences, LLC products

A Whole Blood Assay to assess Individual Patient Responses to Novel Antiviral Therapeutics. While combination anti-retroviral drugs (cART) can control active HIV-1 virus replication, they are not “curative”. Rather, these drugs are required life-long. Developing new therapeutic strategies that can reduce or clear persistent, underlying sources of virus infection will require novel clinical diagnostic assays and tools. Such tools must comprehensively evaluate virologic, immunologic and safety parameters for individuals who may require personalized therapies.

Jericho is developing a new therapeutic drug for FIV infection in cats, working toward a New Animal Drug Application (NADA) with the FDA. Our ongoing studies indicate that Jericho’s small molecule drug candidate can reduce FIV virus levels in chronically-infected cats for many months in the absence of continuing treatment. Extensive testing also indicates that the drug candidate has a good safety profile. Reducing FIV viral loads will help protect damage to cats’ immune systems.

HIV-1 is a virus that attacks the immune system in humans. It targets CD4⁺ T cells (a type of immune cell) that are crucial for fighting off infections. If left untreated, the virus can impair the immune system’s ability to fight off other infections and diseases.